论文部分内容阅读
目的:探讨cortactin在非小细胞肺癌中表达与临床特征的相关性。方法:回顾性分析77例非小细胞肺癌患者的临床病历资料。应用免疫组织化学技术,检测非小细胞肺癌癌组织及正常组织的cortactin表达情况,并进行分析。结果:Cortactin在正常肺组织的血管旁平滑肌细胞胞浆中阳性表达,其阳性率为22.1%(17/77)。在NSCLC组织中,Cortactin于癌细胞胞浆阳性表达,其阳性率为58.4%(45/77),与正常肺组织之间比较具有显著性差异(P<0.05)。Cortactin阳性表达与肿瘤分化程度呈负相关,与TNM分期、淋巴结转移呈正相关。Cortactin阳性表达与患者性别、是否吸烟、病理类型均无明显关系。结论:Cortactin阳性表达高低与NSCLC的临床分期、分化程度及有无淋巴结转移有一定关系,可以作为NSCLC预后的一个参考指标。
Objective: To investigate the correlation between the expression of cortactin and clinical features in non-small cell lung cancer. Methods: A retrospective analysis of 77 patients with non-small cell lung cancer clinical data. Immunohistochemistry was used to detect the expression of cortactin in non-small cell lung cancer tissues and normal tissues, and analyzed. Results: Cortactin was positively expressed in cytoplasm of para-smooth muscle cells in normal lung tissues, with a positive rate of 22.1% (17/77). In NSCLC tissues, Cortactin was positively expressed in cytoplasm of cancer cells, with a positive rate of 58.4% (45/77), which was significantly different from that in normal lung tissues (P <0.05). The positive expression of Cortactin was negatively correlated with the degree of tumor differentiation and positively correlated with TNM stage and lymph node metastasis. The positive expression of Cortactin had no significant relationship with patient’s sex, smoking or pathological type. Conclusion: The positive expression of Cortactin is related to the clinical stage, differentiation and lymph node metastasis of NSCLC, which may be used as a reference index for the prognosis of NSCLC.